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October 5, 2010:1263–6than for tibial arteries. Compared with coronary DES, self-
expanding struts are thicker, the drug-free interstices are wider,
and the dosimetry per volume of plaque is lower. Thus,
predicting the effectiveness of below-the-knee DES based on
previous SFA trials may be deceptive.
. Although limb salvage and relief of rest pain are the primary
goals of critical limb ischemia therapy, we propose that ex-
tended arterial patency is an additional end point that deserves
consideration. The mantra that “patency need only be main-
tained long enough to affect healing” is derived from observa-
tion that long-term bypass patency is suboptimal. Previous
studies (referenced in the PaRADISE [Preventing Amputa-
tions Using Drug Eluting Stents] trial), demonstrated excellent
short-term DES patency. Recently, Balzer et al. (2) reported
that 83% of Cypher stents (Cordis Corp., Bridgewater, New
Jersey) (n  341) were patent at 18 months. Whereas bypass
surgery demonstrates time-dependent decremental graft pa-
tency and limb salvage, data from the PaRADISE trial and
Balzer et al. (2) suggests that stent patency and limb salvage
remain nearly constant after the first 6 months. Thus, DES may
facilitate long-term patency translating into fewer repeat inter-
ventions and reduced health care costs.
. Reducing mortality in critical limb ischemia remains a signifi-
cant challenge. However, a DES-centered endovascular strat-
egy may offer significant improvement over current therapy.
The 1-year mortality in the PaRADISE trial was 11%. The
median age of death was 80 years (95% confidence interval: 74
to 86 years), which is comparable to expected actuarial survival.
In comparison, first-year mortality in the BASIL (Bypass
Versus Angioplasty in Severe Ischaemia of the Leg) trial (3) was
20%, and in the PREVENT III trial (4), mortality was 15%
even though patients were a mean of 7 years younger. We
postulate that PaRADISE’s apparent survival advantage is
related to reduction in deaths from surgery, amputation, proce-
dural complications, and more aggressive secondary prevention.
ontemporary evidence indicates that the time is right for an
ndustry-sponsored U.S. Food and Drug Administration indepen-
ent developmental evaluation designed to investigate the impact
f DES on limb salvage, cost-effectiveness, and quality of life in
atients with critical limb ischemia.
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ransradial Coronary Intervention
adiant or Brilliant?
e read with great interest the recently published review of Rao et
l. (1) regarding the clinical benefits of using the transradial
pproach for percutaneous coronary interventions (PCI). The
aper outstandingly demonstrates how deeply a technical modifi-
ation might influence our current clinical practice. Despite these
enefits, the paper attracts the reader’s attention to the low
doption rate of this technique that is primarily supplied by the
ears and thoughts from the learning curve of the undevoted
perators. In the current correspondence, we would like to extend
he Rao et al. (1) discussion with the findings of 2 recent
bservations.
Rao et al. (1) cited and discussed 2 comprehensive meta-
nalyses of randomized comparisons between the transradial PCI
nd transfemoral PCI approaches (2,3). Although these studies
emonstrated a significant reduction in bleeding- and access
ite-related complications, they failed to find a significant link
etween the frequency of adverse cardiovascular events or mortal-
ty. It should be noted that these analyses included studies
erformed predominantly in elective settings and thus the benefit
f the higher-risk patients may have been concealed by the
ow-risk cases that may have formed the majority. In a recent
eta-analysis of 12 studies involving 3,324 patients with ST-
egment elevation myocardial infarction, we demonstrated that
eyond the bleeding benefit, radial, when compared to transfemo-
al, approach reduced the risk of death, myocardial infarction,
rgent revascularization, or stroke by 44% (odds ratio [OR]: 0.56
95% confidence interval (CI): 0.39 to 0.79]; p  0.001) and
ortality by 46% (OR: 0.54 [95% CI: 0.33 to 0.86]; p 0.01) (4).
oreover, there were no differences in procedural times and in
ime to reperfusion between the 2 access routes. Fluoroscopic times
ere longer in cases of transradial PCI; however, there was
ignificant heterogeneity among studies in these parameters.
Another trial that might add important observations to this
opic is the RAPTOR (Radial Access versus conventional femoral
uncTure: Outcome and Resource effectiveness in a daily routine)
tudy (5). The RAPTOR study was a prospective, randomized,
ingle-center trial to compare radial versus femoral access in an
nselected population. The study has demonstrated that an im-
ediate, ad hoc switch to the transradial program is feasible for an
nterventional site with operators experienced in femoral access.
he trial showed that transradial PCI was not associated with
onger procedural or radiation times, nor with higher rates of
ccess site failures. Procedural and fluoroscopic times and radiation
oses were only greater in case of the diagnostic angiographies, but
ot for PCIs.
In conclusion, the use of transradial PCI is not only beneficial to
educe bleeding but also for ischemic complications and mortality
n high-risk patients undergoing coronary interventions. The
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October 5, 2010:1263–6APTOR study demonstrates that it is safe and effective to change
ur clinical practice even from one day to the other. Longer
uoroscopic times might be attributable to the manipulation
uring the diagnostic phase that can be significantly reduced by
raining and experience.
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eply
e thank Drs. Komo´csi and Aradi for their insight regarding our
eview (1) of transradial percutaneous coronary intervention (PCI).
irst, we agree that practice change from femoral to a radial
pproach is feasible. We changed to the radial approach while
orking in predominantly transfemoral catheterization laborato-
ies. We also agree that procedure and fluoroscopy times, as well as
ccess site crossover rates, can be reduced significantly with
ncreased radial experience.
Second, they are correct that the mortality risk associated with
leeding may be dependent on the patient’s presentation (2). Their
eta-analysis of studies comparing radial and femoral PCI in acute
T-segment elevation myocardial infarction (3) is provocative but
oes not provide definitive evidence that transradial PCI directly
educes mortality. Their analysis included both randomized andbservational comparisons of radial and femoral PCI. This intro-
uces confounding into the analysis because the radial approach is
sed more often in patients at lower risk for bleeding and ischemia
4), and subsequently who are at lower risk for mortality. In
ddition, transradial PCI directly reduces bleeding only at the
ascular access site. Two studies (5,6) have demonstrated that
solated groin hematomas, the most common type of bleeding seen
ith transfemoral PCI, do not correlate with mortality. With the
xception of preventing retroperitoneal hematomas or transfusion
7), it is difficult to explain the mortality reductions seen with
ransradial PCI in observational studies. A well-designed, random-
zed, international trial is still needed before one can definitively
onclude that transradial PCI reduces mortality. The success of
uch a trial depends on the willingness of operators to randomize
atients to either a radial or femoral approach, rather than relying
n observational data to drive a major shift in clinical practice.
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